Autoimmune liver diseases encompass chronic immune mediated liver diseases that are infrequent but impactful. Patients present across the whole spectrum of ages and have both the risk of developing advanced liver disease as well as significant symptom burden. Therapies are currently limited but there are significant efforts in children and adults to improve the care of patients with autoimmune liver disease.
Upon completion of the conference, participants will be able to:
Understand who gets autoimmune liver disease and how they present.
Appreciate why patients get autoimmune liver disease based on scientific insight.
Reflect on the current strategies to treat patients with autoimmune liver disease.
Learn about the challenges involved in developing new therapies for patients with autoimmune liver disease and how current unmet needs may be addressed in the future.
Furthermore, the knowledge gained from this meeting can be applied and enhanced as the interactive format of the meeting will strive to:
Foster informal exchange between leaders in the field and engage young investigators.
Foster research collaboration on autoimmune liver disease within Canada, North America and beyond.
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and accredited by the Canadian Association for the Study of the Liver. Participants can claim up to a maximum of 11 study credits.
Meeting attendees who are specialist physicians may claim their credits directly online by visiting MAINPORT to record learning and outcomes.
The Canadian Association for the Study of the Liver (CASL) and the Canadian Liver Foundation (CLF) acknowledge the following organizations for their support of our mission of “bringing liver research to life” to benefit the liver health of all Canadians through research, education, patient support and advocacy: